Kintara Therapeutics

company

About

Kintara Therapeutics is engaged in developing and commercializing therapies for the treatment of cancer patients.

  • 1 - 10

Details

Last Funding Type
Grant
Industries
Biotechnology,Health Care,Medical
Founded date
Jan 1, 2010
Number Of Employee
1 - 10
Operating Status
Active

Kintara Pharmaceuticals, Inc. engages in developing and commercializing cancer therapies in orphan and other cancer indications for the treatment of patients failing modern targeted or biologic therapy. The company’s principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in clinical trials stage for the treatment of refractory glioblastoma multiforme, a form of brain cancer. Kintara Pharmaceuticals, Inc. also has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the development of VAL-083 used in treating chronic myelogenous leukemia and lung cancer. The company was founded in 2010 and is headquartered in Vancouver, Canada.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
Kintara Therapeutics has raised a total of — in funding over 2 rounds. Their latest funding was raised on Jan 12, 2022 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 12, 2022 Grant 1 Luxembourg National Research Fund Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Kintara Therapeutics is funded by 1 investors. Luxembourg National Research Fund are the most recent investors.
Investor Name Lead Investor Funding Round
Luxembourg National Research Fund Yes Grant